Cargando…
The position of renal denervation in treatment of hypertension: an expert consensus statement
Hypertension is an important risk factor for cardiovascular disease. In the Netherlands, there are approximately 2.8 million people with hypertension. Despite treatment recommendations including lifestyle changes and antihypertensive drugs, most patients do not meet guideline-recommended blood press...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bohn Stafleu van Loghum
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807711/ https://www.ncbi.nlm.nih.gov/pubmed/36001280 http://dx.doi.org/10.1007/s12471-022-01717-4 |
_version_ | 1784862775643734016 |
---|---|
author | Zeijen, V. J. M. Kroon, A. A. van den Born, B. H. Blankestijn, P. J. Meijvis, S. C. A. Nap, A. Lipsic, E. Elvan, A. Versmissen, J. van Geuns, R. J. Voskuil, M. Tonino, P. A. L. Spiering, W. Deinum, J. Daemen, J. |
author_facet | Zeijen, V. J. M. Kroon, A. A. van den Born, B. H. Blankestijn, P. J. Meijvis, S. C. A. Nap, A. Lipsic, E. Elvan, A. Versmissen, J. van Geuns, R. J. Voskuil, M. Tonino, P. A. L. Spiering, W. Deinum, J. Daemen, J. |
author_sort | Zeijen, V. J. M. |
collection | PubMed |
description | Hypertension is an important risk factor for cardiovascular disease. In the Netherlands, there are approximately 2.8 million people with hypertension. Despite treatment recommendations including lifestyle changes and antihypertensive drugs, most patients do not meet guideline-recommended blood pressure (BP) targets. In order to improve BP control and lower the risk of subsequent cardiovascular events, renal sympathetic denervation (RDN) has been introduced and studied as a non-pharmacological approach. While early data on the efficacy of RDN showed conflicting results, improvements in treatment protocols and study design resulted in robust new evidence supporting the potential of the technology to improve patient care in hypertensive subjects. Recently, 5 randomised sham-controlled trials demonstrated the safety and efficacy of the technology. Modelling studies have further shown that RDN is cost-effective in the Dutch healthcare setting. Given the undisputable disease burden along with the shortcomings of current therapeutic options, we postulate a new, clearly framed indication for RDN as an adjunct in the treatment of hypertension. The present consensus statement summarises current guideline-recommended BP targets, proposed workup and treatment for hypertension, and position of RDN for those patients with primary hypertension who do not meet guideline-recommended BP targets (see central illustration). |
format | Online Article Text |
id | pubmed-9807711 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Bohn Stafleu van Loghum |
record_format | MEDLINE/PubMed |
spelling | pubmed-98077112023-01-04 The position of renal denervation in treatment of hypertension: an expert consensus statement Zeijen, V. J. M. Kroon, A. A. van den Born, B. H. Blankestijn, P. J. Meijvis, S. C. A. Nap, A. Lipsic, E. Elvan, A. Versmissen, J. van Geuns, R. J. Voskuil, M. Tonino, P. A. L. Spiering, W. Deinum, J. Daemen, J. Neth Heart J Review Article Hypertension is an important risk factor for cardiovascular disease. In the Netherlands, there are approximately 2.8 million people with hypertension. Despite treatment recommendations including lifestyle changes and antihypertensive drugs, most patients do not meet guideline-recommended blood pressure (BP) targets. In order to improve BP control and lower the risk of subsequent cardiovascular events, renal sympathetic denervation (RDN) has been introduced and studied as a non-pharmacological approach. While early data on the efficacy of RDN showed conflicting results, improvements in treatment protocols and study design resulted in robust new evidence supporting the potential of the technology to improve patient care in hypertensive subjects. Recently, 5 randomised sham-controlled trials demonstrated the safety and efficacy of the technology. Modelling studies have further shown that RDN is cost-effective in the Dutch healthcare setting. Given the undisputable disease burden along with the shortcomings of current therapeutic options, we postulate a new, clearly framed indication for RDN as an adjunct in the treatment of hypertension. The present consensus statement summarises current guideline-recommended BP targets, proposed workup and treatment for hypertension, and position of RDN for those patients with primary hypertension who do not meet guideline-recommended BP targets (see central illustration). Bohn Stafleu van Loghum 2022-08-24 2023-01 /pmc/articles/PMC9807711/ /pubmed/36001280 http://dx.doi.org/10.1007/s12471-022-01717-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Review Article Zeijen, V. J. M. Kroon, A. A. van den Born, B. H. Blankestijn, P. J. Meijvis, S. C. A. Nap, A. Lipsic, E. Elvan, A. Versmissen, J. van Geuns, R. J. Voskuil, M. Tonino, P. A. L. Spiering, W. Deinum, J. Daemen, J. The position of renal denervation in treatment of hypertension: an expert consensus statement |
title | The position of renal denervation in treatment of hypertension: an expert consensus statement |
title_full | The position of renal denervation in treatment of hypertension: an expert consensus statement |
title_fullStr | The position of renal denervation in treatment of hypertension: an expert consensus statement |
title_full_unstemmed | The position of renal denervation in treatment of hypertension: an expert consensus statement |
title_short | The position of renal denervation in treatment of hypertension: an expert consensus statement |
title_sort | position of renal denervation in treatment of hypertension: an expert consensus statement |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807711/ https://www.ncbi.nlm.nih.gov/pubmed/36001280 http://dx.doi.org/10.1007/s12471-022-01717-4 |
work_keys_str_mv | AT zeijenvjm thepositionofrenaldenervationintreatmentofhypertensionanexpertconsensusstatement AT kroonaa thepositionofrenaldenervationintreatmentofhypertensionanexpertconsensusstatement AT vandenbornbh thepositionofrenaldenervationintreatmentofhypertensionanexpertconsensusstatement AT blankestijnpj thepositionofrenaldenervationintreatmentofhypertensionanexpertconsensusstatement AT meijvissca thepositionofrenaldenervationintreatmentofhypertensionanexpertconsensusstatement AT napa thepositionofrenaldenervationintreatmentofhypertensionanexpertconsensusstatement AT lipsice thepositionofrenaldenervationintreatmentofhypertensionanexpertconsensusstatement AT elvana thepositionofrenaldenervationintreatmentofhypertensionanexpertconsensusstatement AT versmissenj thepositionofrenaldenervationintreatmentofhypertensionanexpertconsensusstatement AT vangeunsrj thepositionofrenaldenervationintreatmentofhypertensionanexpertconsensusstatement AT voskuilm thepositionofrenaldenervationintreatmentofhypertensionanexpertconsensusstatement AT toninopal thepositionofrenaldenervationintreatmentofhypertensionanexpertconsensusstatement AT spieringw thepositionofrenaldenervationintreatmentofhypertensionanexpertconsensusstatement AT deinumj thepositionofrenaldenervationintreatmentofhypertensionanexpertconsensusstatement AT daemenj thepositionofrenaldenervationintreatmentofhypertensionanexpertconsensusstatement AT zeijenvjm positionofrenaldenervationintreatmentofhypertensionanexpertconsensusstatement AT kroonaa positionofrenaldenervationintreatmentofhypertensionanexpertconsensusstatement AT vandenbornbh positionofrenaldenervationintreatmentofhypertensionanexpertconsensusstatement AT blankestijnpj positionofrenaldenervationintreatmentofhypertensionanexpertconsensusstatement AT meijvissca positionofrenaldenervationintreatmentofhypertensionanexpertconsensusstatement AT napa positionofrenaldenervationintreatmentofhypertensionanexpertconsensusstatement AT lipsice positionofrenaldenervationintreatmentofhypertensionanexpertconsensusstatement AT elvana positionofrenaldenervationintreatmentofhypertensionanexpertconsensusstatement AT versmissenj positionofrenaldenervationintreatmentofhypertensionanexpertconsensusstatement AT vangeunsrj positionofrenaldenervationintreatmentofhypertensionanexpertconsensusstatement AT voskuilm positionofrenaldenervationintreatmentofhypertensionanexpertconsensusstatement AT toninopal positionofrenaldenervationintreatmentofhypertensionanexpertconsensusstatement AT spieringw positionofrenaldenervationintreatmentofhypertensionanexpertconsensusstatement AT deinumj positionofrenaldenervationintreatmentofhypertensionanexpertconsensusstatement AT daemenj positionofrenaldenervationintreatmentofhypertensionanexpertconsensusstatement |